Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, non-interventional, prospective study. The observation period
comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with
partial-onset epilepsy not sufficiently controlled with one AED, until the first visit that
occurs between 6 and 9 months of follow-up. The observation period will end after 9 months of
follow-up even if the final assessment is not performed.